Please Wait
Applying Filters...
Menu
Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 2Trodelvy

02 2Trodelvy - U.S.

PharmaCompass

01

Brand Name : Trodelvy - U.S.

Sacituzumab Govitecan

arrow
Antibody Engineering
Not Confirmed

Brand Name : Trodelvy - U.S.

arrow
Antibody Engineering
Not Confirmed

Sacituzumab Govitecan

Main Therapeutic Indication : Oncology

Currency : USD

2020 Revenue in Millions : 49

2019 Revenue in Millions : 0

Growth (%) : Acquired by Gilead from Immunomedics

blank

02

Brand Name : Trodelvy - U.S.

Sacituzumab Govitecan

arrow
Antibody Engineering
Not Confirmed

Brand Name : Trodelvy - U.S.

arrow
Antibody Engineering
Not Confirmed

Sacituzumab Govitecan

Main Therapeutic Indication : Oncology

Currency : USD

2021 Revenue in Millions : 380

2020 Revenue in Millions : 49

Growth (%) : 676

blank

03

Brand Name : Trodelvy

Sacituzumab Govitecan

arrow
Antibody Engineering
Not Confirmed

Brand Name : Trodelvy

arrow
Antibody Engineering
Not Confirmed

Sacituzumab Govitecan

Main Therapeutic Indication : Oncology

Currency : USD

2022 Revenue in Millions : 680

2021 Revenue in Millions : 380

Growth (%) : 79

blank

04

Brand Name : Trodelvy

Sacituzumab Govitecan

arrow
Antibody Engineering
Not Confirmed

Brand Name : Trodelvy

arrow
Antibody Engineering
Not Confirmed

Sacituzumab Govitecan

Main Therapeutic Indication : Oncology

Currency : USD

2023 Revenue in Millions : 1,063

2022 Revenue in Millions : 680

Growth (%) : 56

blank